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ABSTRACT 
Cholera caused by toxigenic Vibrio cholerae is a major public health problem 
confronting developing countries, where outbreaks occur in a regular seasonal pattern 
and are particularly associated with poverty and poor sanitation. The disease is 
characterized by a devastating watery diarrhea which leads to rapid dehydration, and 
death occurs in 50 to 70% of untreated patients. Prophylactic vaccination for cholera 
was initially thought as a means of control programme. Although cholera vaccine 
strains have been constructed with all known toxin (El Tor hemolysin, CT, Zot, and 
Ace) genes deleted or inactivated, some volunteers fed with these strain still develop 
diarrhea probably due to the presence of cell- associated CHO cell- elongating factor, 
cef 
In this study we therefore, have tried to clone and mutate this cef gene with the 
hope of eliminating its residual diarrheagenic effect, thus the development of improved 
VCUSM2 and VCUSM4 vaccine candidates. Accordingly, the cef factor was amplified 
from wild type Vibrio cholerae which was subsequently cloned into a cloning vector, 
pTZ57R/T at Eco321 site. The cef gene in pTZ57R was digested with Psyl 
enzyme, to allowing insertional mutational ligation to occur at this site. The PCR 
amplified kan resistance gene cassette from pTOP02.1 was used to insertionally 
mutate the cef gene as well as a marker for selection fallowing transformation. The 
selected clones with kan marker were screened by PCR for confirmation and 
subsequently verified by DNA sequencing 
XIV 
1.0 INTRODUCTION 
1.1 Cholera - The Disease 
Cholera (8, 13, 14) is characterized by a severe watery diarrhea caused by 
toxigenic Vibrio 1 cholerae, which colonizes the small intestine and produces an 
enterotoxin, cholera toxin (CT). Cholera (or Asiatic cholerae) is generally a disease 
frequently associated with poverty and poor sanitation. Cholera infection is seen as a 
result of consumption of contaminated water supplies, consumption of shellfish 
harvested from feacally polluted coastal waters and also, from non-polluted waters 
since Vibrio cholerae 01 is part of the autochthonous micro biota of these waters. 
Hence, oral - fecal route of transmission of infection. 
Symptoms of Asiatic cholera may vary from a mild, watery diarrhea to an 
acute diarrhea, with characteristic rice water stools, reflecting the conversion of the 
intestinal contents to a thin material like barley soup. Onset of the illness is generally 
sudden, with incubation periods varying from 6 hours to 5 days. The patient's eyes 
become gray and sink into their orbit (Figure 1.1 ). The skin is wrinkled, dry, and cold, 
and muscular cramps occur in the arms and legs. Despite the continuous thirst, 
sufferers cannot hold fluids. The blood thickens, urine production ceases, and the 
sluggish blood flow to the brain lead to shock and coma. In untreated cases, the 
mortality rate may reach 70 percent. 
All people are believed to be susceptible to infection, but individuals with 
damaged or undeveloped immunity, reduced gastric acidity, or malnutrition may 
suffer more severe forms of the illness. 
1 Vibrio, derived from the Latin which means 'to vibrate'. 
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1.1.1 Vibrio cholerae -The causative organism 
The bacterium responsible for Asiatic or epidemic cholera is Vibrio cholerae 
(Figure 1.2). It is first isolated by Robert Koch in 1883. Vibrio cholerae are Gram 
negative (Figure 1.3), usually curved rods (vibrios), measuring 3-4 Jlm with a single 
flagellum at one end. Vibrio cholerae are highly motile organism with a distinctive 
rapid to - and - fro (darting) movement and best seen using dark- field microscopy. 
These organisms are sensitive to acid pH but tolerate alkaline pH very well. 
Alkaline peptone water (pH 8.6) containing lOg/1 sodium chloride is a good 
enrichment medium for Vibrio cholerae (typically marine organisms) and other vibrio 
species growth. Vibrio cholerae is a sucrose fermenting organism, therefore it appears 
as large colonies of 2-3 mm in diameter, smoothly convex, yellow in color with a fine 
consistency on TCBS (Figure 1.4) culture plate. Definite and rapid growth (6-8 hours) 
in nutrient agar is another cultural feature of Vibrio cholerae. Vibrio cholerae grow 
over the temperature ranging from 16 - 42°C with optimum growth at 37°C. The 
organism is aerobic in nature and gives a very sparse growth appearance under 
anaerobic condition. ( 15) 
The cholera vibrios cause many distinctive reactions. They are oxidase 
positive. They ferment sucrose and mannose but not arabinose, and they produce acid 
but not gas. Vibrio cholerae also possesses lysine and ornithine decarboxylase, but not 
arginine dihydrolase. 
Vibrio species possess 0 (somatic) and H (flagellar) antigens. The flagellar 
antigens of Vibrio. cholerae are shared with many water vibrios and therefore are of 
no use in distinguishing strains causing epidemic cholera. 0 antigens, however, do 
distinguish strains of Vibrio cholerae into 139 known serotypes. Almost all of these 
strains of Vibrio cholerae are non-virulent. Until the emergence of the Bengal strain 
2 
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Figure 1.7 
Patient's condition following diarrhea caused by Vibrio cholerae. 
Electron micrograph of cholera causing organism- Vibrio cholerae. 
Microscopic morphology of Vibrio cholerae; Gram stain. 
Vibrio cholerae growth on TCBS culture plate. The yellow colonies 
results from citrate utilization and the formation of acid from utilization of the sucrose 
in the medium. (I) 
Figure 1.5 Vibrio cholerae - Positive string test. Vibrio cholerae when mixed in a 
drop of0.5% sodium deoxycholate, produce an extremely viscid suspension that can 
be drawn into a string with an inoculating loop. ( 1) 
Figure 1.6 Positive slide agglutination test for Vibrio cholerae using polyvalent 0 
anti- serum. (1) 
Figure 1.7 Chicken erythrocyte agglutination test. Classic strains of Vibrio 
cholerae do not agglutinate chicken erythrocytes (top), in contrast to the El Tor 
biotype (bottom) which is capable of agglutinating the red cells. ( 1) 
(which is "non-01 ") a single serotype, designated 01 , has been responsible for 
epidemic cholera. 
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Serogroup 01 Vibrio cholerae ( 13) has three distinct subtypes, named Ogawa, 
Inaba and Hikojima, and each biotype may display the "classical" or El Tor biotype. 
Test types employed in differentiating the 'Classical' and 'El Tor' biotype of Vibrio 
cho/erae, includes production of a hemolysin, sensitivity to selected bacteriophages, 
sensitivity to polymyxin, the Voges-Proskauer test for acetoin and hemagglutination 
(Figure 1. 7). 
As mentioned earlier, both biotypes (El Tor and classical) are further sub-
typed into Ogawa, Inaba and Hikojima (Figure 1.8). These serotypes are differentiated 
in agglutination and vibriocidal antibody tests on the basis of their dominant heat-
stable lipopolysaccharide somatic antigens (Figure 1.6). The cholera group has a 
common antigen, A, and the serotypes are differentiated by the type-specific antigens, 
B (Ogawa) and C (lnaba). An additional serotype, Hikojima, which has both specific 
antigens, is rare. 
Biotype EITor Classical 
I I 1 
Serotype Ogawa lnaba (HikoPma) Ogawa lnaba (Hikojima) 
Antigens A,B A,C (A, B. C) A,B A,C (A, B. C) 
Figure 1.8 Biotype and sub-serotype classification of Serogroup 01 Vibrio 
cholerae. 
1.1.2 Epidemiology (25) 
Outbreaks of cholera cause deaths estimated at 120,000 annually worldwide 
and many more cases each year, of which the vast majority occurs in children. 
Hallmarks of the epidemiology of cholera include (i) a high degree of clustering of 
cases by location and season, (ii) highest rates of infection in children I to 5 years of 
age in areas of endemic infection, (iii) antibiotic resistance patterns that frequently 
change from year to year, (iv) clonal diversity of epidemic strains, and (v) protection 
against the disease by improved sanitation and hygiene and preexisting immunity. 
Cholera has been categorized as one of the "emerging and reemerging infections" 
threatening many developing countries. 
Cholera appears to exhibit three major epidemiologic patterns: heavily 
endemic, neoepidemic (newly invaded, cholera-receptive areas), and, in developed 
countries with good sanitation, occasional limited outbreaks. These patterns probably 
depend largely on environmental factors (including sanitary and cultural aspects), the 
prior immune status or antigenic experience of the population at risk, and the inherent 
properties of the vibrios themselves, such as their resistance to gastric acidity, ability 
to colonize, and toxigenicity. Recent studies, however, have suggested that cholera 
vibrios can persist for some time in shellfish, algae or plankton in coastal regions of 
infected areas and it has been claimed that they can exist in "a viable but non-
culturable state." 
There have been eight great pandemics. Epidemic cholera was first described 
in 1 563 by Garcia del H uerto, a Portuguese physician at Goa, India. The mode 0 f 
transmission of cholera by water was proven in 1849 by John Snow, a London 
physician. In 1883, Robert Koch successfully isolated the cholera vibrio 
("Kommabacillus") from the intestinal discharges of cholera patients and proved 
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conclusively that it was the agent of the disease during the fifth pandemics. The sixth 
pandemic and presumably the fifth pandemic were caused by Vibrio cholerae of the 
classical biotype. The seventh pandemic (Figure 1.9) is the most extensive of the 
pandemics in geographic spread and in duration, and the causative agent is V. ibrio 
cholerae 01 of the El Tor biotype. However, in 1992, Vibrio cholerae belonging to a 
non-01 serogroup (now referred to as 0139) caused large epidemics of cholera in 
India and Bangladesh and spread to some other countries; this may represent the 
beginning of the eighth pandemic. 
Figure 1.9 
(CDC) (28) 
The global spread of cholera during the seventh pandemic, 1961-1971. 
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Figure 1.10 Cholera, reported number of cases and case fatality rates, 1950-1998. 
Adapted from WHO Report on Global Surveillance ofEpidemic; 2001 (28) 
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1. 1.3 Transmission 
Poor sanitation practice (20) in highly populated areas harboring endemic 
toxigenic strains are the source of occasional outbreaks due to contamination of 
drinking water and I or improper food preparation. Contaminated water with free -
living Vibrio cholerae cells are probably the main origin of epidemics, follow to a 
lesser extent by contamination food, especially seafood products (Figure 1.12) like 
oysters, crabs, and shellfish. There have been reports of bottled water contamination 
with toxigenic Vibrio cholerae. The evidence suggested that carbonated water was 
safer than non - carbonated water, due to the organism's poor acid tolerance. 
Figure 1.12 Cholera causing contaminated seafood products. 
Vibrio cholerae infections normally starts with the oral ingestion of food or 
water contaminated with Vibrio cholerae (Figure 1.13) (20). Subsequently, the 
bacteria must pass through and survive the gastric acid barrier of the stomach, then 
penetrate the mucus lining that coats the intestinal epithelia. The infectious dose in 
human is determined to be fairly high, ranging from 106 to 10 11 colony forming units 
(c.f.u). The surviving bacterium adheres to and colonizes the intestinal epithelial cells 
' 
eventually producing the toxin substances and causing cholera symptoms. The 
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pnmary site of Vibrio cholerae colonization is the small intestine. During the 
transition from the environment to the hwnan body the bacterial cells are exposed to 
series of changes, such as the temperature, acidity, and osmolarity. They must also 
survive the intestinal environment, which contains growth inhibitory substances like 
bile salts and organic acids, and also factors of the innate immune system, such as 
complement secreted by intestinal epithelial cells and defensins produced by Paneth 
cells. Therefore, Vibrio cholerae has developed the ability to survive, colonize, and 
express virulence factors in spite of, and possibly in response to, harsh environmental 
conditions. 
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Figure 1 .13 Infection cycle of Vibrio cholerae. (20) 
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1.1.4 Pathogenesis 
Cholera toxin (26) 
The growing cholera vibrios elaborate the cholera enterotoxin (CT or 
choleragen), a polymeric protein (MW 84,000) consisting of two major domains or 
regions. (21) The A region (MW 28,000), responsible for biologic activity of the 
enterotoxin, is linked by noncovalent interactions with the B region (MW 56,000), 
which is composed of five identical noncovalently associated peptide chains of MW 
11,500. The B region, also known as choleragenoid, binds the toxin to its receptors on 
host cell membranes. It is also the immunologically dominant portion of the 
holotoxin. The structural genes that encode the synthesis of CT reside on a 
transposon-like element in the Vibrio cholerae chromosome. The amino acid 
sequences of these structurally, functionally, and immunologically related 
enterotoxins are very similar. Their differences account for the differences in 
physicochemical behavior and the antigenic distinctions that have been noted. There 
are at least two antigenically related but distinct forms of cholera enterotoxin, called 
CT-1 and CT-2. Classical 01 Vibrio cholerae and the Gulf Coast El Tor strains 
produce CT -1 whereas most other El Tor strains and 0139 produce CT -2. Synthesis 
of CT and other virulence-associated factors such as toxin-coregulated pili are 
believed to be regulated by a transcriptional activator, Tox R, a transmembrane DNA-
binding protein. 
The molecular events in these diarrheal diseases involve an interaction 
between the enterotoxins and intestinal epithelial cell membranes. The toxins bind 
through region B to a glycolipid, the GMI ganglioside, which is practically ubiquitous 
in eukaryotic cell membranes. Following this binding, the A region, or a major 
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portion of it known as the A 1 peptide (MW 21 ,000), penetrates the host cell and 
enzymatically transfers ADP-ribose from nicotinamide adenine dinucleotide (NAD) 
to a target protein, the guanosine 5'-triphosphate (GTP)-binding regulatory protein 
associated with membrane-bound adenylate cyclase. The ADP-ribosylation reaction 
essentially locks adenylate cyclase in its "on mode" and leads to excessive production 
of cyclic adenosine 51-monophosphate (cAMP). The final effect is hypersecretion of 
chloride and bicarbonate followed by water, resulting in the characteristic isotonic 
voluminous cholera stool. 
Intestinal colonization 
There are several characteristics of pathogenic Vibrio cholerae that are 
important determinants of the colonization process. These include adhesins, 
neuraminidase, motility, chemotaxis and toxin production. If the bacteria are able to 
survive the gastric secretions and low pH of the stomach, they are well adapted to 
survival in the small intestine. Vibrio cholerae is resistant to bile salts and can 
penetrate the mucus layer of the small intestine, possibly aided by secretion of 
neuraminidase and proteases. They withstand propulsive gut motility. by their own 
swimming ability and chemotaxis directed against the gut mucosa. 
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Figure 1.14 Mode of action of cholera toxin ( CT) ( 12 ). 
(A) Adenylate cyclase, located in the basolateral membrane of intestinal epithelial cells, is regulated by 
G proteins. CT binds via the B - subunit pentamer to the GMt ganglioside receptor inserted into the 
lipid bilayer. (B) The A subunit enters the cell, probably via endosomes, and is proteolytically cleaved, 
with subsequent reduction of the disulfide bond to yield At and A2 peptides. The A1 peptides is 
activated by ARFs and transfers an ADP- moiety (ADPR) from NAD to the a subunit of the Gs 
protein. The ADP ribosylated a subunit dissociates from the other subunits of Gsa and activates 
adenylate cyclase, thereby increasing the intracellular cAMP concentration. (C) Increased cAMP 
activates protein kinase A, leading to protein phosphorylation. In crypt cells, the protein 
phosphorylation leads to increase cr secretion, and in villous cells, it leads to decreased Nacr coupled 
absorption. 
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Specific adherence of Vibrio cholerae to the intestinal mucosa is probably 
mediated by long filamentous fimbriae that form b undies at the poles of the cells. 
These fimbriae have been termed Tcp pili (for toxin coregulated pili), because 
expression of these pili genes is co-regulated with expression of the cholera toxin 
genes. Not much is known about the interaction of Tcp pili with host cells, and the 
host cell receptor for these fimbriae has not been identified. Tcp pili share amino acid 
sequence similarity with N-methylphenylalanine pili of Pseudomonas and Neisseria. 
Two other possible adhesins in Vibrio cholerae are a surface protein that 
agglutinates red blood cells (hemagglutinin) and a group of outer membrane proteins 
which are products of the acf(accessory colonization factor) genes. (13) Acf mutants 
have been shown to have reduced ability to colonize the intestinal tract. It has been 
suggested that Vibrio c holerae might use these n on-fimbrial adhesins to mediate a 
tighter binding to host cells than is attainable with fimbriae alone. 
Vibrio cholerae produces a protease originally called mucinase that degrades 
different types of protein including fibronectin, lactoferrin and cholera toxin itself. Its 
role in virulence is not known but it probably is not involved in colonization since 
mutations in the mucinase gene (designated hap for hemagglutinin protease) do not 
exhibit reduced virulence. It has been suggested that the mucinase might contribute to 
detachment rather than attachment. Possibly the vibrios would need to detach from 
cells that are being sloughed off of the mucosa in order to reattach to newly formed 
mucosal cells. 
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1.1.5 Treatment (12) 
The key to therapy is provision of adequate rehydration until the disease has 
run its course (usually 1 - 5 days in the absence of antimicrobial therapy). 
Rehydration can be accomplished by, (a) intravenous infusion of fluids (in severe 
cases), (b) oral rehydration (in mild or moderate dehydration) and, (c) antimicrobial 
agents. 
For both adults and childrens intravenous replacement solution should be 
infused as soon (rapidly) as possible. The precise rates of fluid administration should 
be adjusted according to monitoring of the patient's state of hydration and continuing 
stool losses. The intravenous fluid chosen for rehydration should be adequate to 
replace the isotonic fluid and electrolyte losses of cholera. The World Health 
Organization (WHO) recommends Ringer's lactate as the best commercial solution. 
Isotonic saline corrects hypovolumia, but potassium, base and glucose must be 
supplemented. 
Patients with mild or moderate dehydration can receive initial fluid 
replacement to repair water and electrolyte deficits exclusively by the oral route. Oral 
rehydration are accomplished with an oral rehydration solution namely, ORS as 
recommended by WHO. This solution provides adequate quantities of electrolytes to 
correct the deficits associated with diarrheal dehydration and an optimal amount of 
glucose to facilitate the absorption of sodium and water. Vomiting rarely prevents 
successful use of ORS and is not a contraindication to its use. 
Antimicrobial agents I therapy play a secondary in decreasing the severity of 
illness and the duration of excretion of the organism. This rapid clearance of vibrios 
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from stool may help to reduce secondary transmission of cholera, especially 1n 
hospitals, treatment centres, and refugee settings. Antimicrobial therapy 1s 
immediately started after initial rehydration and correction of acidosis. Tetracycline is 
the drug of choice for antibiotic treatment of cholera, also, Doxycycline. In instances 
of tetracycline resistant isolates, alternative antimicrobial agents may be issued, 
namely; Erythromycin, Trimethoprim - Sulfamethoxazole, Furazolidone and 
Ciprofloxacin. 
1.1.6 Control and prevention (12)(20)(23) 
Strategies for the prevention and control of cholera are: 
a) Early detection of epidemics through diarrheal disease surveillance and 
investigation of severe cases and cluster of illness. 
b) Education to promote good personal hygiene emphasizing proper hand-
washing with soap and food preparation techniques. Bathing in potentially 
contaminated open water should also be discouraged. 
c) Construction and maintenance of sewage disposal facilities. 
d) Provision and protection of safe and plentiful water and storage (e.g.: homes 
and restaurants). Simple and inexpensive methods of domestic water 
disinfection and storage have been developed and they reduce the risk of 
cholera and diarrheal diseases. Point-of-use disinfection and the appropriate 
use 0 f safe water storage containers are important in maintaining the water 
supply. 
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Besides hygienic and sanitary control measures and cholera surveillance, one 
of the main efforts at combating cholera epidemics is directed towards the 
development and use of modem vaccine strategies. Cholera is predicted to have a high 
potential for successful prevention by vaccination. Efficient protection is dependent 
on the biotype: infection with the classical biotype shows more conserved protection 
against different serotypes (Inaba, Ogawa, and Hikojima) of classical strains, and El 
Tor - derived protection is more labile against different El Tor isolates. Vaccination 
strategies consists of, (a) whole cell vibrio preparations and, (b) attenuated live 
vaccine strain, both which delivered orally. 
Whole cell toxoids an oral combination vaccine (7) consisting of 1 mg of 
purified CT B subunit and killed V. cholerae cells was first developed by 
Svennerholm and Holmgren. The whole - cell component in a dose of vaccine 
contains three Vibrio cholerae strains totaling 1011 cells. The strains represent both 
biotypes and serotypes and killed by either heat or formalin. However, this 
preparation only provides short lived preparation and proved to be reactogenic. 
Live attenuated vaccine strains (preparation) (7) closely mimics infection 
derived immunity. Therefore, live strains are more efficiently taken up M cells, the 
major antigen presenting cells in the gut, than are killed cells. Attenuated strains have 
been constructed by both chemical mutagenesis and as well as using recombinant 
DNA techniques to prepare mutants which are deleted several hundred nucleotide 
base pairs. 
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1.2 Chinese Hamster Ovary (CHO) cell- elongating factor (cef) (5)(16)(24) 
1.2.1 History- cef factor 
In 1988, a genetically manipulated El Tor strain (JBK70) was developed in 
which the ctx A gene coding for the A subunit of cholera toxin (CT) was deleted. But 
when JBK 70 was fed to volunteer, more than half developed mild diarrhea. This 
findings had lead for search for a possible additional virulence. This search has 
resulted in the identification of zonula occludens toxin (Zot), and accessory toxin 
(Ace). 
In 1993, when CVD110 a strain (derivative of El Tor Ogawa Vibrio cholerae 
01) with the DNA sequences coding for Zot, Ace and CT deleted and with a mercury 
resistance gene and ctxB inserted into the hlyA locus, was fed to volunteers, 7 out of 
10 still developed mild diarrhea. This result suggests the presence of an additional 
virulence factor in Vibrio cholerae. 
Henceforth, in year 2000, a research team had finally identified the factor 
which causes the mild diarrheagenic effect following vaccination with potential 
vaccine strain (JBK 70) and, named it after its remarkable elongation effect on 
Chinese hamster ovary cells, thus cell elongation factor (cej). Though studies shows 
that cejfactor was unrelated to cholera toxin, but it is still identified as enterotoxin as 
such, since it enabled to explain the production of gastrointestinal symptoms In 
volunteers given to Vibrio cholerae strains devoid of all other known toxins. 
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1.2.2 Characteristic of CHO cell elongation factor 
CHO cell elongation factor was released from an El Tor strain of Vibrio 
cholerae when subjected to treatment with lysozyme - EDTA or polymyxin B. 
Lysozyme - EDT A released material wasp referred to that polymyxin B I ysate for 
purification. 
The partly purified cef factor by anion chromatography and elution from a pH 
3 - 9 iso-electric focusing gel shows specific activity of the partially purified cef factor 
approximately 4.8 X 105 CHO cell units I mg of protein and 2.56 X 106 CHO cell 
units I mg of protein respectively (see Figure 1.15). 
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Figure 1.15 Partial purification of a CHO cell elongating factor from Vibrio 
cholerae 0 1. 
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Biochemically, ceffactor was found to be located at a pi of approximately 3.8 
on an IEF gel. IEF gel eluate of cef factor on 8 - 25% SDS - PAGE gel shows CHO 
cell activity associated with one, 85 kDa band via silver stain or Coomassie blue stain 
(Figure 1.16). 
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Figure 1.16 Analysis of partially purified cef on polyacrylan1ide gels. Lane 1 shows 
CHO cell activity at approximately 85 kDa on an 8 - 25% SDS - pAGE gel. 
When blots of the 85 kDa band from the SDS - PAGE gel were subjected to 
ammo terminal sequence analysis, the sequence was determined to be 
XGDETNSSGASTEWYESYIQQ for amino acids 1 - 22. This unique amino acids 
sequence matched accurately the sequence data from Vibrio cholerae Nl6961 when 
the database from the Institute for Genomic Research (TIGR) was searched. 
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Physical heat treatment at 1 00°C completely destroys CHO cell activity of cef 
factor indicates that the factor is heat labile. Following treatment with subtilisin and 
proteinase K, approximately 80% and 50% of the original CHO cell activity 
respectively was lost suggesting susceptibility of this factor to the mentioned 
proteolytic enzymes. 
Effects of various other treatments was also studied on CHO cell activity of 
ceftoxin namely, heat treatment at 5 6°C for 15 min, treatment with anti - cholera 
toxin, ganglioside GMt, etc (see Figure 1.17). However, unlike the above mentioned 
treatments after - effects, the CHO cell activity of cef toxin was retained - 100%. 
Activity which was not decreased by pre - incubation with anti - serum to cholera 
toxin suggests that cef is not immunologically related to cholera toxin. As for the 
uninhibited CHO cell activity of ceftoxin by ganglioside GMt and mixed gangliosides 
that was observed indicates that the cellular receptor for cef is not a ganglioside as 
seen in CT (cholera toxin) and LT (heat labile toxin). 
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Figure 1.17 Effect of various treatments on CHO cell activity of ceftoxin. 
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In the quest of studying enzymatic activity of cef toxin, the toxin was 
subjected for esterase and phospholipase assays. The toxin was assayed with a variety 
of esterase and phospholipase substrates. The enzymatic activity was then read at 
405nm following 60 minutes at 37°C. Assay result shows that nil activity of lipase 
and phopholipase activity was detected. However, cef activity was observed on 4 - 10 
carbon ester when ester substrates were tested. 
CHO treated with cef toxin was found not to bear any effect on cyclic AMP 
(cAMP) and prostaglandin (PGE2) in CHO cells following a 24 hours incubation. In 
contrast, CHO cells treated with CT shows greatly elevated cAMP levels and slightly 
elevated PGE2 levels. 
Cef was observed to exhibit enterotoxic activity via its effect in producing 
fluid accumulation in the sealed infant mice model. However, the exact mechanism 
by which the cef causes CHO such effect remains unknown. 
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2.0 OBJECTIVES 
•!• To clone the cefgene of Vibrio cholerae in pTZ57R vector. 
•!• To obtain kanamycin resistance gene cassette from pTOPO vector by PCR 
amplification. 
•!• To mutate the cef gene at Psyl site by insertion of kanamycin resistance gene 
cassette. 
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EXPERIMENTAL OVERVIEW 
PCR amplification of cef gene from wild type Vibrio cholerae 
PCR amplified kan 
gene cassette from 
pTOP02.1 
Cloning into pTZ57R/T vector 
l 
pTZ57R cef construct 
Ligation of kan gene cassette at Psy 1 site of cef gene 
l 
pTZ57R cef:: kan construct 
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